NCT02026973View on ClinicalTrials.gov

Impact of Endogenous E2 on SSI and GH Rebound

PHASE1CompletedINTERVENTIONAL

Enrollment

62

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Normal Healthy Volunteers

Interventions

DRUG

Fulvestrant

DRUG

Anastrozole

DRUG

Placebo

DRUG

Somatostatin

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER